SG Americas Securities LLC Acquires Shares of 11,861 908 Devices Inc. (NASDAQ:MASS)

SG Americas Securities LLC bought a new position in shares of 908 Devices Inc. (NASDAQ:MASS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,861 shares of the company’s stock, valued at approximately $133,000.

Several other hedge funds have also recently modified their holdings of the stock. American Century Companies Inc. acquired a new stake in 908 Devices in the 3rd quarter worth about $87,000. GSA Capital Partners LLP acquired a new position in 908 Devices during the third quarter worth about $112,000. AQR Capital Management LLC purchased a new position in 908 Devices in the 3rd quarter worth approximately $116,000. AWM Investment Company Inc. purchased a new stake in shares of 908 Devices in the third quarter valued at approximately $3,740,000. Finally, Northern Trust Corp boosted its stake in 908 Devices by 4.9% during the third quarter. Northern Trust Corp now owns 184,944 shares of the company’s stock worth $1,232,000 after buying an additional 8,582 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

908 Devices Trading Down 3.5 %

Shares of MASS stock opened at $5.59 on Thursday. The company’s 50-day moving average price is $6.89 and its 200-day moving average price is $7.10. 908 Devices Inc. has a twelve month low of $4.85 and a twelve month high of $12.51. The stock has a market cap of $183.97 million, a price-to-earnings ratio of -4.95 and a beta of 0.93.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. The business had revenue of $14.40 million during the quarter, compared to the consensus estimate of $14.16 million. 908 Devices had a negative net margin of 72.47% and a negative return on equity of 21.09%. The business’s revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) EPS. As a group, equities research analysts predict that 908 Devices Inc. will post -1.29 EPS for the current year.

Insider Buying and Selling at 908 Devices

In related news, CFO Joseph H. Iv Griffith sold 5,698 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $7.00, for a total transaction of $39,886.00. Following the completion of the sale, the chief financial officer now directly owns 89,711 shares of the company’s stock, valued at approximately $627,977. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other 908 Devices news, CFO Joseph H. Iv Griffith sold 5,698 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $7.00, for a total transaction of $39,886.00. Following the completion of the transaction, the chief financial officer now owns 89,711 shares of the company’s stock, valued at $627,977. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin J. Knopp sold 9,071 shares of 908 Devices stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $7.00, for a total transaction of $63,497.00. Following the sale, the chief executive officer now owns 411,981 shares of the company’s stock, valued at $2,883,867. The disclosure for this sale can be found here. Insiders have sold 20,001 shares of company stock worth $139,955 over the last quarter. 27.80% of the stock is currently owned by company insiders.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.